Persistence with biologic agents for the treatment of rheumatoid arthritis in Japan.
| Title: | Persistence with biologic agents for the treatment of rheumatoid arthritis in Japan. |
|---|---|
| Authors: | Jörg Mahlich1,2 jmahlich@its.jnj.com, Rosarin Sruamsiri1,3 |
| Source: | Patient Preference & Adherence. Aug2016, Vol. 10, p1509-1519. 11p. |
| Subject Terms: | *RHEUMATOID arthritis treatment, *BIOLOGICALS, *DISEASE prevalence, *COMORBIDITY, *PUBLIC health |
| Geographic Terms: | JAPAN |
| Abstract: | Background: To assess persistence rates of biologic agents for the treatment of rheumatoid arthritis in Japan. Methods: Based on Japanese claims data of 16,214 patients between 2012 and 2014, 6-, 12-, and 18-month persistence rates of different biologic agents were calculated. Determinants of persistence were assessed by means of a multivariate Cox proportional hazard model controlling for age, sex, and comorbidities. A sensitivity analysis was performed with different definitions of persistence and parametric survival analysis. Results: Overall persistence rates in Japan are high and reach 86% after 1 year in the entire sample. The persistence rate for the biologic-naïve subpopulation is above 95%. Persistence is higher for older patients (hazard ratio 0.60 [95% confidence interval 0.40-0.91] for >75 years compared to ⩽60 years) and lower for patients with a high comorbidity score (hazard ratio 1.33; 95% confidence interval 1.03-1.70 for Charlson Comorbidity Index score 3-5 compared to ⩽2). We found a high variation of persistence between different drugs. Conclusion: Japanese rheumatoid arthritis patients have a high persistence rate of biologic treatments. However, multiple factors affect the persistence rate of Japanese patients, including age, comorbidities, and patient type. Naïve patients tend to have a higher persistence rate than continuing biologic patients. [ABSTRACT FROM AUTHOR] |
| Copyright of Patient Preference & Adherence is the property of Dove Medical Press Ltd and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.) | |
| Database: | Academic Search Complete |
| FullText | Links: – Type: pdflink Text: Availability: 0 CustomLinks: – Url: https://resolver.ebsco.com/c/xy5jbn/result?sid=EBSCO:a9h&genre=article&issn=1177889X&ISBN=&volume=10&issue=&date=20160801&spage=1509&pages=1509-1519&title=Patient Preference & Adherence&atitle=Persistence%20with%20biologic%20agents%20for%20the%20treatment%20of%20rheumatoid%20arthritis%20in%20Japan.&aulast=J%C3%B6rg%20Mahlich&id=DOI:10.2147/PPA.S110147 Name: Full Text Finder (for New FTF UI) (s8985755) Category: fullText Text: Find It @ SCU Libraries MouseOverText: Find It @ SCU Libraries |
|---|---|
| Header | DbId: a9h DbLabel: Academic Search Complete An: 118285608 AccessLevel: 6 PubType: Academic Journal PubTypeId: academicJournal PreciseRelevancyScore: 0 |
| IllustrationInfo | |
| Items | – Name: Title Label: Title Group: Ti Data: Persistence with biologic agents for the treatment of rheumatoid arthritis in Japan. – Name: Author Label: Authors Group: Au Data: <searchLink fieldCode="AR" term="%22Jörg+Mahlich%22">Jörg Mahlich</searchLink><relatesTo>1,2</relatesTo><i> jmahlich@its.jnj.com</i><br /><searchLink fieldCode="AR" term="%22Rosarin+Sruamsiri%22">Rosarin Sruamsiri</searchLink><relatesTo>1,3</relatesTo> – Name: TitleSource Label: Source Group: Src Data: <searchLink fieldCode="JN" term="%22Patient+Preference+%26+Adherence%22">Patient Preference & Adherence</searchLink>. Aug2016, Vol. 10, p1509-1519. 11p. – Name: Subject Label: Subject Terms Group: Su Data: *<searchLink fieldCode="DE" term="%22RHEUMATOID+arthritis+treatment%22">RHEUMATOID arthritis treatment</searchLink><br />*<searchLink fieldCode="DE" term="%22BIOLOGICALS%22">BIOLOGICALS</searchLink><br />*<searchLink fieldCode="DE" term="%22DISEASE+prevalence%22">DISEASE prevalence</searchLink><br />*<searchLink fieldCode="DE" term="%22COMORBIDITY%22">COMORBIDITY</searchLink><br />*<searchLink fieldCode="DE" term="%22PUBLIC+health%22">PUBLIC health</searchLink> – Name: SubjectGeographic Label: Geographic Terms Group: Su Data: <searchLink fieldCode="DE" term="%22JAPAN%22">JAPAN</searchLink> – Name: Abstract Label: Abstract Group: Ab Data: Background: To assess persistence rates of biologic agents for the treatment of rheumatoid arthritis in Japan. Methods: Based on Japanese claims data of 16,214 patients between 2012 and 2014, 6-, 12-, and 18-month persistence rates of different biologic agents were calculated. Determinants of persistence were assessed by means of a multivariate Cox proportional hazard model controlling for age, sex, and comorbidities. A sensitivity analysis was performed with different definitions of persistence and parametric survival analysis. Results: Overall persistence rates in Japan are high and reach 86% after 1 year in the entire sample. The persistence rate for the biologic-naïve subpopulation is above 95%. Persistence is higher for older patients (hazard ratio 0.60 [95% confidence interval 0.40-0.91] for >75 years compared to ⩽60 years) and lower for patients with a high comorbidity score (hazard ratio 1.33; 95% confidence interval 1.03-1.70 for Charlson Comorbidity Index score 3-5 compared to ⩽2). We found a high variation of persistence between different drugs. Conclusion: Japanese rheumatoid arthritis patients have a high persistence rate of biologic treatments. However, multiple factors affect the persistence rate of Japanese patients, including age, comorbidities, and patient type. Naïve patients tend to have a higher persistence rate than continuing biologic patients. [ABSTRACT FROM AUTHOR] – Name: AbstractSuppliedCopyright Label: Group: Ab Data: <i>Copyright of Patient Preference & Adherence is the property of Dove Medical Press Ltd and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract.</i> (Copyright applies to all Abstracts.) |
| PLink | https://login.libproxy.scu.edu/login?url=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=a9h&AN=118285608 |
| RecordInfo | BibRecord: BibEntity: Identifiers: – Type: doi Value: 10.2147/PPA.S110147 Languages: – Code: eng Text: English PhysicalDescription: Pagination: PageCount: 11 StartPage: 1509 Subjects: – SubjectFull: JAPAN Type: general – SubjectFull: RHEUMATOID arthritis treatment Type: general – SubjectFull: BIOLOGICALS Type: general – SubjectFull: DISEASE prevalence Type: general – SubjectFull: COMORBIDITY Type: general – SubjectFull: PUBLIC health Type: general Titles: – TitleFull: Persistence with biologic agents for the treatment of rheumatoid arthritis in Japan. Type: main BibRelationships: HasContributorRelationships: – PersonEntity: Name: NameFull: Jörg Mahlich – PersonEntity: Name: NameFull: Rosarin Sruamsiri IsPartOfRelationships: – BibEntity: Dates: – D: 01 M: 08 Text: Aug2016 Type: published Y: 2016 Identifiers: – Type: issn-print Value: 1177889X Numbering: – Type: volume Value: 10 Titles: – TitleFull: Patient Preference & Adherence Type: main |
| ResultId | 1 |